<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> increases the risk of <z:e sem="disease" ids="C0010068" disease_type="Disease or Syndrome" abbrv="">coronary heart disease</z:e> (CHD) 2-4-fold, making CHD the predominant cause of <z:hpo ids='HP_0011420'>death</z:hpo> in patients with <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Currently identified risk factors include, among others, <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e>, <z:hpo ids='HP_0000822'>hypertension</z:hpo> and <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidaemia</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Since studies show that intensive glycaemic control alone will not overcome the excess CHD risk, reducing blood pressure by any means and <z:chebi fb="23" ids="18059">lipid</z:chebi> levels by using <z:chebi fb="0" ids="35664">statins</z:chebi> and fibrates is effective in reducing CHD and associated mortality in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>Other interventions include aspirin therapy and the use of angiotensin-converting enzyme (ACE) inhibitors </plain></SENT>
</text></document>